About

COMPANY INTRODUCTION

AUROPHAR Pharmaceuticals Co. Ltd was found in 2013 by a group of experts with extensive knowledge and experience in both the prescription (ETC) and non-prescription (OTC) markets. At AUROPHAR, we are committed to delivering high-quality products to patients in Vietnam.

In 2019, AUROPHAR underwent a strategic restructuring, ushering in a new era of growth and development. The company made significant additions to its leadership team leading by Ms. Hang Le as the Chief Executive Officer (CEO) with over 15 years of experience in the global healthcare industry. AUROPHAR’s product portfolio also receives constant consultation on the most updated treatment guideline by a doctor with 20 years in ETC pharmaceutical sector in many multinational corporations.

This infusion of in-depth experience and expertise brought fresh perspectives and ideas to the table, propelling AUROPHAR towards new heights with new strategy:

Shifting our product portfolio towards the ETC market in Vietnam

Focusing our portfolio on active ingredients with scientifically proven breakthrough in curbing chronic diseases (most notably heart diseases, diabetes and blood clotting)

Making our products more affordable by setting up long-term strategic partnership with top-tier manufacturers globally and applying new technology in corporate management.

With a dedicated team of professionals, a strong focus on R&D, quality and cost reduction, AUROPHAR Pharmaceuticals Co. Ltd. is well-poised to continue making significant contributions to the healthcare landscape of Vietnam and delivering our commitment to improving patients’ life.

Vision

To establish AUROPHAR as the premier purveyor of the finest healthcare products and solutions for chronic-disease diagnosed patients in Vietnam while maintaing our uncompromising principles while we grow.